Trial Profile
Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Rifapentine (Primary) ; Ethambutol; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampicin
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ACTG Study A5349; TBTC Study 31
- 24 Mar 2023 Results of population pharmacokinetic analysis of INH in patients with drug-susceptible TB using data from S31/A5349, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 24 Mar 2023 Results deriving data from NCT02410772; developing Mathematical Model for Selecting Regimen Composition and Duration Based on Phenotype for Patients with Drug-Susceptible Tuberculosis, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 24 Mar 2023 Results assessing PK-safety relationships and perform simulations to inform who can benefit from optimized rifapentine doses, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.